BIM is a proapoptotic member of the B‐cell CLL/lymphoma 2 (BCL2) family of proteins, and its upregulation is required for TKIs to induce apoptosis in kinase‐driven cancers. It has been reported that EGFR‐mutated NSCLC patients with BIM polymorphism experienced significantly worse responses to TKIs than patients without this polymorphism (Ng et al., 2012). This evidence concerns the gene EGFR and non-small cell lung carcinoma.